HOME >> BIOLOGY >> NEWS
AVAX Technologies receives an additional $3.0 Million (AUD) investment in Australian joint venture from Australian Vaccine Technologies Ltd.

Kansas City, MO, April 6, 2000 -- AVAX Technologies, Inc. (NASDAQ: AVXT) today announced that its Australian joint venture, AVAX Australia Pty. Ltd. has received an additional $3.0 million (AUD) investment from Neptunus International Holdings Limited (NIHL), which was recently renamed Australian Vaccine Technologies Ltd. (AVT). AVAX Australia holds the rights to manufacture and market AVAX Technologies' autologous cancer vaccine (AC Vaccine™) for melanoma, M-Vax™, in Australia and has similar rights in New Zealand. M-Vax is AVAX's lead cancer vaccine and is currently being evaluated in the U.S. in a multicenter pivotal registration trial for Stage III melanoma and in a Phase 2 trial for Stage IV melanoma.

Under the joint venture agreement, AVAX Australia has now received a total of $7.0 million (AUD) from AVT for a 35% interest in the joint venture entity. AVT also has the option to purchase an additional 15% interest for $3.0 million (AUD). Under the terms of the agreement, AVAX Technologies has been granted an option to purchase common stock equivalent to 5% of AVT's fully diluted shares. AVT began trading on the Australian Stock Exchange (ASX) under the symbol "AVT" on March 10, 2000.

Jeffrey M. Jonas, M.D., President and CEO of AVAX Technologies, Inc., stated, "We are very pleased to see AVT increasing their investment in our promising joint venture in Australia. This additional capital investment represents their enthusiasm for the potential of our product and our marketing strategy. We continue to believe that the Australian market allows us to truly demonstrate the validity of our business model and our ability to effectively market individualized product."

In 1999, AVAX announced that it had received notice from Australia's Therapeutic Goods Administration (TGA) that M-Vax may be made available for commercial sale, subject only to licensure of a manufacturing facility. M-Vax, a therapeutic cancer vacc
'"/>

Contact: Olga Fleming
ofleming@cpronline.com
201-641-2408 ext. 34
AVAX Technologies, Inc.
5-Apr-2000


Page: 1 2

Related biology news :

1. Regeneration Technologies introduces advancements at AAOS
2. Palatin Technologies PT-141 increases sexual behavior in female animals
3. NASA Materials Conference Features Science Results, Experts on Technologies for Exploration
4. AVAX Technologies M-Vax™ cancer vaccine extends five-year overall survival in patients with lymph node metastatic melanoma
5. AVAX Technologies O-Vax™ cancer vaccine induces positive immunological and clinical outcomes in patients with advanced ovarian cancer
6. AVAX Technologies AC Vaccine™ improves relapse-free survival
7. AVAX Technologies M-Vax™ cancer vaccine induces T cell mediated immune reactions in patients with metastatic melanoma
8. First International Congress on Telehealth and Multimedia Technologies Story Ideas
9. Technologies Track, Map Fish Behavior
10. USGS Contributions Enhance Public Health Research, Scientists Showcase Technologies At San Diego Meeting
11. UT Southwestern receives $1.78 million grant for obesity research as part of NIH Roadmap initiative

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/19/2020)... ... , ... The former Jason "Furious" Styles of "Boyz n the Hood" (1991), ... The TV program highlights a large variety of subjects that have an impact on ... a dive into the world of applied academics. The episode will cover education in ...
(Date:3/13/2020)... ... March 13, 2020 , ... ... Vivorte Inc. to be the exclusive distributor of the Louisville-based company’s orthobiologics portfolio. ... medical education expertise to distribute Vivorte’s calcium phosphate-based bone allograft (Trabexus) and calcium ...
(Date:3/10/2020)... ... March 10, 2020 , ... ... Board of Directors. Dr. Narasimhan is Senior Vice President of Strategic Initiatives, Portfolio ... the Board of Directors of Cytonus, we are extremely pleased to welcome Manisha ...
Breaking Biology News(10 mins):
(Date:3/3/2020)... ... March 03, 2020 , ... Ideal Implant Incorporated Founder and ... technology at the IMCAS Innovation Shark Tank 2020 in Paris, France in January. ... and aesthetic science industries that promise to revolutionize medical practices in their fields. ...
(Date:2/21/2020)... ... February 20, 2020 , ... ... capability to perform complex, efficient and elegant chemistry. Humans have been increasingly ... our own goals. , Through rapidly evolving technologies and strategies for modern ...
(Date:2/19/2020)... ... February 18, 2020 , ... Intech , the ... a new and unified global brand identity, as it celebrates its 20th anniversary. ... as well as an enthusiasm for designing and manufacturing state-of-the-art medical devices, Intech ...
(Date:2/10/2020)... ... , ... R3 Medical Training announced it is now registering for its next ... course is hands on involving real patients and stem cell biologics, with every attendee ... Cell Training Course has received rave reviews from attendees, who love the hands on ...
Breaking Biology Technology:
Cached News: